Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

GENENTA SCIENCE SPA

Contributing Author

Recent Articles by GENENTA SCIENCE SPA

Sep-15	Sophia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into Orbit GNTA GlobeNewswire
Jul-23	Genenta-backed Sophia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm GNTA GlobeNewswire
Jul-22	Genenta-Backed Sophia High Tech Reports Fiscal Year 2025 Results GNTA GlobeNewswire
Apr-23	Genenta signs Definitive Agreements with Sophia High Tech GNTA GlobeNewswire
Mar-27	Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sophia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs GNTA -14.29% GlobeNewswire
Mar-24	Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini GNTA +8.19% GlobeNewswire
Mar-13	Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University GNTA GlobeNewswire
Feb-27	Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform GNTA GlobeNewswire
Jan-27	Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator GNTA +18.46% GlobeNewswire
Dec-19	Genenta Science Provides Update on CEO Ownership GNTA GlobeNewswire
Nov-24	Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial GNTA +5.95% GlobeNewswire
Oct-26	Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares GNTA -46.45% GlobeNewswire
Oct-24	Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production GNTA +91.95% GlobeNewswire
Jul-01	Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals GNTA +25.45% GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)